Reference entry
Tesa/IPA Protocol (Tesa-IPA)
Tesamorelin + Ipamorelin GH Secretagogue Blend
Overview
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
Enhanced GH promotes protein synthesis and lean tissue preservation.
GH secretagogues often improve deep sleep quality.
Mechanism
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
Research areas
- The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
- The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
- Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
- Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
- Enhanced GH promotes protein synthesis and lean tissue preservation.
- GH secretagogues often improve deep sleep quality.
- Enhanced GH supports tissue repair and recovery from exercise.
- Restoring more youthful GH levels may provide anti-aging benefits.
- Tesamorelin has shown improvements in lipid parameters in studies.
- Increased GH leads to increased IGF-1 production.
Research notes
- Injection site reactions (redness, itching)
- Water retention (usually transient)
- Tingling or numbness in extremities
- Joint stiffness
- Increased hunger (Ipamorelin effect)
- Severe injection site reactions
- Significant swelling or edema
- Signs of glucose dysregulation
- Severe joint pain
- Allergic reactions
- Active malignancy (GH may promote tumor growth)
- Diabetic retinopathy
- Pregnancy or breastfeeding
- Pituitary disorders
- Hypersensitivity to components
References
FAQs
Why combine tesamorelin and ipamorelin instead of using them separately?
Tesamorelin and ipamorelin work on complementary GH-release pathways (GHRH vs GHRP receptors), producing synergistic GH release greater than either alone. The combination mimics natural pulsatile GH secretion more effectively while maintaining safety with less cortisol/prolactin elevation than GHRPs used solo.
What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?
5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for athletic recovery; 10/3 for fat-loss focused protocols with body composition optimization goals.
Should the Tesa/IPA blend be taken on an empty stomach?
Yes, both tesamorelin and ipamorelin work best on an empty stomach (2-3 hours before eating). Evening injection (before bed) on an empty stomach optimizes the protocol by aligning with natural nighttime GH pulses and avoiding food-induced metabolic interference.
Can Tesa/IPA be combined with CJC-1295 or other GH secretagogues?
No, combining Tesa/IPA (which already contains both GHRH and GHRP pathways) with additional GHRPs or GHRH analogs risks excessive pituitary stimulation. The blend is specifically designed as a complete dual-pathway system that shouldn't require additional GH secretagogues.